Virax Biolabs Group (Virax Biolabs Group) Price-to-Tangible-Book : 0.19 (As of Apr. 30, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Price-to-Tangible-Book?

As of today (2024-04-30), Virax Biolabs Group's share price is $0.6287. Virax Biolabs Group's Tangible Book per Share of Sep. 2023 for the quarter that ended in Sep. 2023 was $3.29. Hence, Virax Biolabs Group's Price to Tangible Book Ratio of today is 0.19.

The historical rank and industry rank for Virax Biolabs Group's Price-to-Tangible-Book or its related term are showing as below:

VRAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.19 Med: 1.21 Max: 8.36
Current: 0.19

During the past 4 years, Virax Biolabs Group's highest Price to Tangible Book Ratio was 8.36. The lowest was 0.19. And the median was 1.21.

VRAX's Price-to-Tangible-Book is ranked better than
98.28% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs VRAX: 0.19

A closely related ratio is called PB Ratio. As of today, Virax Biolabs Group's share price is $0.6287. Virax Biolabs Group's Book Value per Sharefor the quarter that ended in Sep. 2023 was $3.50. Hence, Virax Biolabs Group's P/B Ratio of today is 0.18.

Virax Biolabs Group Price-to-Tangible-Book Historical Data

The historical data trend for Virax Biolabs Group's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Price-to-Tangible-Book Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Price-to-Tangible-Book

1.21

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Price-to-Tangible-Book	Get a 7-Day Free Trial			-	-	8.36	1.21	0.99

Competitive Comparison of Virax Biolabs Group's Price-to-Tangible-Book

For the Biotechnology subindustry, Virax Biolabs Group's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Price-to-Tangible-Book falls into.

Virax Biolabs Group Price-to-Tangible-Book Calculation

Virax Biolabs Group's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Sep. 2023 )
	=	0.6287	/	3.289
	=	0.19

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Virax Biolabs Group Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.